Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRC-063 Adult Laboratory Classroom Study for ADHD
NCT03618030Phase 3Completed
- Sponsor
- Purdue Pharma
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Purdue Pharma. Primary endpoint: Permanent Product Measure of Performance - Total Score at 13 hours. Started Aug 2018; status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03618030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618030.